Evidence map›Paper›PMID 31305530›Full record

ArticleJournal of visualized experiments : JoVE2019

NMR-Based Activity Assays for Determining Compound Inhibition, IC50 Values, Artifactual Activity, and Whole-Cell Activity of Nucleoside Ribohydrolases.

Brian J Stockman, Abinash Kaur, Julia K Persaud, Maham Mahmood, Samantha F Thuilot, Melissa B Emilcar, Madison Canestrari, Juliana A Gonzalez, Shannon Auletta, Vital Sapojnikov and 2 more

Open access · greenAbstract readVideo-Audio Media
In one paragraph

Article in Journal of visualized experiments : JoVE, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.1field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Target Engagement Assays in Early Drug Discovery.Journal of medicinal chemistry · 2025
    Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Brian J StockmanDepartment of Chemistry, Adelphi University; bstockman@adelphi.edu.
Abinash KaurDepartment of Chemistry, Adelphi University.
Julia K PersaudDepartment of Chemistry, Adelphi University.
Maham MahmoodDepartment of Chemistry, Adelphi University.
Samantha F ThuilotDepartment of Chemistry, Adelphi University.
Melissa B EmilcarDepartment of Chemistry, Adelphi University.
Madison CanestrariDepartment of Chemistry, Adelphi University.
Juliana A GonzalezDepartment of Chemistry, Adelphi University.
Shannon AulettaDepartment of Chemistry, Adelphi University.
Vital SapojnikovDepartment of Chemistry, Adelphi University.
Wagma CaravanDepartment of Chemistry, Adelphi University; Department of Chemistry, Washington University in St. Louis.
Samantha N MuellersDepartment of Chemistry, Adelphi University; Department of Chemistry, Boston University.
Adelphi University · USBoston University · US

Funding

Nucleoside ribohydrolases as targets for Trichomonas vaginalis therapeutic agents. This project will evaluate two essential nucleoside ribohydrolase enzymes as targets for novel antitrichomonal drugs.R15AI128585 · NIAID · ADELPHI UNIVERSITY · PI STOCKMAN, BRIAN J · 2017 to 2017
$311k
NIAID NIH HHS R15 AI128585
6 · The paper itself

Abstract

NMR spectroscopy is often used for the identification and characterization of enzyme inhibitors in drug discovery, particularly in the context of fragment screening. NMR-based activity assays are ideally suited to work at the higher concentrations of test compounds required to detect these weaker inhibitors. The dynamic range and chemical shift dispersion in an NMR experiment can easily resolve resonances from substrate, product, and test compounds. This contrasts with spectrophotometric assays, in which read-out interference problems often arise from compounds with overlapping UV-vis absorption profiles. In addition, since they lack reporter enzymes, the single-enzyme NMR assays are not prone to coupled-assay false positives. This attribute makes them useful as orthogonal assays, complementing traditional high throughput screening assays and benchtop triage assays. Detailed protocols are provided for initial compound assays at 500 μM and 250 μM, dose-response assays for determining IC50 values, detergent counter screen assays, jump-dilution counter screen assays, and assays in E. coli whole cells. The methods are demonstrated using two nucleoside ribohydrolase enzymes. The use of

Indexed as

Magnetic Resonance SpectroscopyBiological AssayDrug DiscoveryEnzyme InhibitorsEscherichia coliHigh-Throughput Screening AssaysHumansInhibitory Concentration 50N-Glycosyl HydrolasesEnzyme InhibitorsN-Glycosyl Hydrolases

Identifiers

PMID31305530
PMCPMC7061360
OpenAlexW2953406168

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.